First-in-Class Quinoline-Dione-Derived PROTACs: Potent Degraders of Cdc25 Phosphatases for Antitumor Therapy

Dysregulated Cdc25 phosphatases drive tumorigenesis, but their "undruggable" active site (planar and electropositive) has hindered small-molecule inhibitor development. Herein, we report the first-in-class PROTAC degraders targeting Cdc25, derived from the quinoline-dione scaffold, by conjugating <b>NSC663284</b> (a Cdc25 inhibitor) with E3 ligase ligands via optimized linkers. Among them, compound <b>D3</b>, the most potent degrader, induced concentration- and time-dependent degradation of Cdc25A/B/C with DC₅₀ values of 0.97 μM, 2.02 μM, and 4.67 μM, respectively, via a proteasome-dependent pathway. <b>D3</b> can significantly inhibit tumor growth in xenotransplantation models and exhibit a favorable pharmacokinetic profile. Mechanistically, <b>D3</b> exerts antitumor effects by degrading the target protein Cdc25, upregulating p-CDK1/2 levels, and subsequently inducing G₂/M phase cell cycle arrest and apoptosis. This study validates PROTACs as a breakthrough strategy to target "undruggable" Cdc25, provides a novel quinoline-dione-based scaffold for antitumor drug development, and offers a rational design paradigm for tackling intractable phosphatase targets.